-buvir
A hepatitis C NS5B polymerase inhibitor.
- Drugs ending in -buvir: 13
- Approved somewhere: 2
- With a US drug page: 1
Approved and clinical-stage drugs in ChEMBL whose names ending in -buvir, matched by spelling; those with a US drug page link to it.
| Acts on | |||
|---|---|---|---|
| Sofosbuvir | Approved | NS5B | RNA-directed RNA polymerase inhibitor |
| Dasabuvir | Approved | NS5B | RNA-directed RNA polymerase inhibitor |
| Beclabuvir | Phase 3 | NS5B | RNA-directed RNA polymerase negative allosteric modulator |
| Bemnifosbuvir | Phase 3 | โ | โ |
| Deleobuvir | Phase 3 | NS5B | RNA-directed RNA polymerase inhibitor |
| Adafosbuvir | Phase 2 | NS5B | RNA-directed RNA polymerase inhibitor |
| Filibuvir | Phase 2 | NS5B | RNA-directed RNA polymerase inhibitor |
| Lomibuvir | Phase 2 | NS5B | RNA-directed RNA polymerase negative allosteric modulator |
| Nesbuvir | Phase 2 | NS5B | RNA-directed RNA polymerase inhibitor |
| Radalbuvir | Phase 2 | NS5B | RNA-directed RNA polymerase inhibitor |
| Setrobuvir | Phase 2 | NS5B | RNA-directed RNA polymerase inhibitor |
| Tegobuvir | Phase 2 | NS5B | RNA-directed RNA polymerase inhibitor |
| Uprifosbuvir | Phase 2 | NS5B | RNA-directed RNA polymerase inhibitor |
Stem from WHO, The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances (2024); description written by Arca. Drugs, stages, targets and mechanisms from ChEMBL (CC BY-SA 3.0). WHO